Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LAVA 1207

Next Previous
Drug Profile

LAVA 1207

Alternative Names: LAVA-1207

Latest Information Update: 23 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VU University Medical Center
  • Developer Lava Therapeutics; Merck & Co
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 23 Aug 2025 Lava Therapeutics terminates the Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy, Second-line therapy or greater) in Spain, Netherlands, USA (IV) as trial was intended to be a phase I/II trial (but the trial never moved forward to phase II).(NCT05369000)
  • 10 Dec 2024 Discontinued - Phase-I/II for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Netherlands (IV)
  • 10 Dec 2024 Discontinued - Phase-I/II for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Spain (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top